Read Detailed Index stating List of Figures, Tables and Charts Available @ https://www.htfmarketreport.com/reports/857060-global-and-chinese-diabetic-macular-edema-industry-2017-market There are following Chapters to display the Global and Chinese Diabetic Macular Edema market. Chapter 1: About Global and Chinese Diabetic Macular Edema that includes Introduction of Global and Chinese Diabetic Macular Edema , Development, Status and Outlook of Industry Chapter 2: Development, Analysis & Trends of Technology used in Manufacturing of Global and Chinese Diabetic Macular Edema Chapter 3: In-depth information about Global and Chinese Diabetic Macular Edema that includes Company profile, Basic Information, Product Information, Historical data from 2012 to 2017 along with SWOT analysis and Contact information. Chapter 4: Global and Chinese Diabetic Macular Edema Market detailed historical insights from 2012 to 2017 covering global capacity, production and production value [USD] of Diabetic Macular ...
Diabetic retinopathy is a major cause of visual impairment in the United States. Diabetic macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central vision. Data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) estimate that after 15 years of known diabetes, the prevalence of diabetic macular edema is approximately 20% in patients with type 1 diabetes mellitus (DM), 25% in patients with type 2 DM who are taking insulin, and 14% in patients with type 2 DM who do not take insulin.. In a review of three early studies concerning the natural history of diabetic macular edema, Ferris and Patz found that 53% of 135 eyes with diabetic macular edema, presumably all involving the center of the macula, lost two or more lines of visual acuity over a two year period. In the Early Treatment Diabetic Retinopathy Study (ETDRS), 33% of 221 untreated eyes available for follow-up at the 3-year visit, all with edema involving the center of the macula at ...
TY - JOUR. T1 - Cystoid macular edema in the first week after cataract extraction. AU - Klein, Richard M.. AU - Yannuzzi, Lawrence. PY - 1976/5. Y1 - 1976/5. N2 - Fluorescein angiography was safely performed in 100 consecutive cases of cataract extraction during the first postoperative week. Seventy-five percent of the 100 eyes had good quality fluorescein angiograms. Four eyes demonstrated cystoid macular edema. Therefore, the incidence of cystoid macular edema in the first week after cataract surgery was low when compared to the reported incidence (40%) four to six weeks postoperatively.. AB - Fluorescein angiography was safely performed in 100 consecutive cases of cataract extraction during the first postoperative week. Seventy-five percent of the 100 eyes had good quality fluorescein angiograms. Four eyes demonstrated cystoid macular edema. Therefore, the incidence of cystoid macular edema in the first week after cataract surgery was low when compared to the reported incidence (40%) four to ...
This report studies the Diabetic Macular Edema Treatment market size by players, regions, product types and end industries, history data and forecast data 2020-2025. Top Key Players operating in this report are: Genentech, Novartis, GlaxoSmithKline, Eyetech Pharmaceuticals, Alimera Sciences, The report on the Global Diabetic Macular Edema Treatment Market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that players could improve their sales and growth in the global Diabetic Macular Edema Treatment market. It offers detailed analysis of the competition and leading companies of the global Diabetic Macular Edema Treatment market. Here, it concentrates on the recent developments, sales, market value, production, gross margin, and other important factors of the business of top players operating in the ...
Purpose: : To evaluate the use of intravitreal ketorolac as an alternative to steroids in the treatment of macular edema. Methods: : Retrospective non-randomized case series. Inclusion criteria were a previous steroid response or diagnosis of glaucoma and no previous eye surgery within 3 months of intravitreal ketorolac injection and macular edema. Fluorescein angiography and optical coherence tomography were performed at baseline, 1 week, 1 month and 3 months. ETDRS visual acuity was performed at the same intervals. Results: : Total of 7 eyes were reviewed with the following diagnosis: diabetic macular edema (4 eyes), chronic cystoid macular edema (2 eyes) and central retinal vein occlusion (CRVO) with macular edema ( 1 eye). Intravitreal ketorolac dosis was 60 mcg-90 mcg/0.1 ml in diabetic eyes, 200 mcg/0.1 ml in CME eyes and 900 mcg/0.1 ml in CRVO eye. Visual acuity improvement of 2 lines or more were seen in 2 diabetic eyes and 1 eye with CRVO and macular edema. The remainder of the eyes ...
The treatment schedule comprised three monthly injections, after which … The 6- month Ranibizumab for Edema of the Macula in Diabetes (READ-2) study …. Lucentis (ranibizumab) for the Treatment of Diabetic Macular Edema (DME), … monthly treatment with 0.3mg Lucentis, 0.5mg Lucentis or a sham injection.. Dec 12, 2015 … Diabetic macular edema (DME) is one of the most common causes of …. I recommend single-injection therapy when there is significant edema ….. If I started with bevacizumab or ranibizumab, and either metric stalls after three …. Feb 26, 2015 … This exploratory analysis found that, in eyes with center-involved diabetic macular edema and no prior open-angle glaucoma, repeated …. Common Diseases Treated by Intravitreal Injections [edit , edit source] AMD (neovascular age related macular degeneration) CSME/PDR (clinically significant …. What are Anti VEGF agents, and what is their role in managing diabetic retinopathy? Anti VEGF agents (Lucentis, Avastin, Macugen) are ...
The most common reason for decreased vision in diabetic retinopathy is macular edema. Current approaches to macular edema include FDA approved interventions such as laser and better underlying control of the disease and co morbid conditions. Off label interventions include intravitreal triamcinolone and bevacizumab, both of which have been demonstrated to be efficacious; at least in the short term (weeks) but carry significant risks. Surgical approaches are still controversial and have not shown long term benefits. Unfortunately, there are subsets of patients resistant to any of the above therapies. Intravitreal therapies utilizing methotrexate 400 ug (MTX) have been used for other ophthalmologic conditions associated with inflammation driven macular edema. bevacizumab an anti VEGF agent has been utilized in diseases other than macular degeneration with a favorable effect. It is known that certain similar inflammatory mediators play a role in diabetic macular edema. It would be logical to ...
TY - CONF. T1 - Retinal oxygen saturation in relation to retinal thickness in diabetic macular edema. AU - Blindbæk, Søren Leer. AU - Peto, Tunde AU - Grauslund, Jakob. PY - 2017. Y1 - 2017. N2 - Purpose: Retinal oximetry is a non-invasive measure of retinal metabolism. Diabetic retinopathy is associated with increased oxygen saturation in retinal venules. Hence, we examined if there are regional differences in retinal oxygen saturation, and if retinal oxygen saturation is correlated to retinal thickness in patients with diabetic macular edema (DME). Methods: We included 18 patients with DME that all had central retinal thickness (CRT) ,300 µm and were free of active proliferative diabetic retinopathy. Optical coherence tomography (Topcon 3D OCT-2000 spectral domain OCT) was used to evaluate retinal thickness, and oximetry was performed in 50-degree disc-centered images using the Oxymap model T1 (Oxymap, Reykjavik, Iceland). For macular measurements, we used the first traceable macular ...
RnRMarketResearch.com offers "Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023"global research report on its store.. Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge ...
Purpose: To evaluate the effect on clinical practice of the introduction of anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema.. Methods: Two cohorts with clinically significant diabetic macular edema were identified and studied retrospectively. One group began treatment 10 years prior to identification while the other began treatment 3 years prior to identification. Entry vision, final vision, and treatments were tabulated for each group. Treatment cost was calculated using current fee schedules for Medicare and the predominant private insurance carrier for the state of treatment (Alabama). A maximal and minimal cost model was built for both payer type and by anti-VEGF drug.. Results: Treatment in the 10-year-old cohort consisted entirely of laser photocoagulation while treatment in the 3-year-old cohort consisted of a combination of laser photocoagulation and anti-VEGF treatment. The 3 year cohort had fewer laser procedures (1.8 versus 2.4), better visual ...
ASRS member Neil Bressler, MD, Co-Chair of Retina 20/20, is featured in a video from the National Eye Institute on diabetic macular edema that includes details about the Diabetic Retinopathy Clinical Research Networks recent breakthrough research on injections of medications into the middle cavity of the eye. The research indicates that injections of a drug designed to stop abnormal factors (produced in the eye of some people with diabetes) from damaging the eye, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina, the light-sensitive tissue lining the back of the eye.. Click to view video. ...
Purpose: To evaluate the effectiveness of focal laser for the treatment of diabetic macular edema (DME) performed by ophthalmology residents. Methods: This retrospective chart review studies DME patients treated in a resident clinic with focal laser. Visual acuity (VA), OCT central subfield thickness (CST), and maximum subfield thickness (MST) at initial, 1-month, and 6-month visits were recorded. Results: For 32 reviewed patients, the average VA was 20/58 initially and 20/39 at 6 months (p=0.18). Mean CST was 311 µm initially and 305 µm at 6 months (p=0.09). Mean MST was 413 µm initially and 382 µm at 6 months (p=0.007). Factors favoring success are initial CST |400 |µm, treatment of localized microaneurysms, and prior focal laser treatments. Conclusion: Focal laser performed by residents was effective in decreasing MST and maintained visual acuity. Initial CST, localized microaneurysms, and repeat focal treatment predicted improved outcomes.
Diabetic Macular Edema or DME is an Ophthalmology Disease that is Diagnosed and Treated at the Retina Center of New Jersey which has Locations in Bloomfield, NJ, Teaneck, NJ, North Bergen, NJ and Ramsey, NJ treated by Dr. Patrick Higgins, Dr. Kurt Jackson, Dr. Lauren Kallina, Dr. Lee Angioletti, Dr. Justin Gutman, Dr. Louis V. Angioletti Jr.
To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who
[42 Pages Report] Check for Discount on Diffuse Diabetic Macular Edema Global Clinical Trials Review, H1, 2016 report by GlobalData. GlobalDatas clinical trial report, Diffuse Diabetic Macular...
TY - JOUR. T1 - Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. AU - Wang, Jianmin. AU - Ibrahim, Mohamed. AU - Turkcuoglu, Peykan. AU - Hatef, Elham. AU - Khwaja, Afsheen. AU - Channa, Roomasa. AU - Do, Diana V. AU - Nguyen, Quan Dong. PY - 2010/10/1. Y1 - 2010/10/1. N2 - Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of ...
Summary Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2016, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appea
title:Role of Laser Photocoagulation Versus Intravitreal Triamcinolone Acetonide in Angiographic Macular Edema in Diabetes Mellitus. Author:Aggarwal Somesh VP, Shah Sonali N, Bharwada Rekha M, Billore Puja S. Keywords:Diabetes Mellitus, Macular Edema, Photocoagulation. Type:Original Article. Abstract:Aims: To compare the effect of laser photocoagulation and intravitreal triamcelone acetonide in the treatment of diabetic macular edema Material and Methods: During the period of one year 100 patients having diabetic macular edema were enrolled in the project.Fluorescein angiography was carried out in all patients to confirm the diagnosis of macular edema. Patients were randomly assigned into two groups. One group was treated with laser photocoagulation and other group was given intravitreal triamcinolone. Observations: 82 % of patients were of type 2 diabetes while 18 % had type 1 diabetes. 40 % patients had the disease for more than 15 years. 48 % patients had diffuse macular edema on fluorescein ...
DME can occur in people with diabetic retinopathy, a type of diabetic eye disease that can cause the growth of abnormal blood vessels in the retina. The macula is the area of the retina used when looking straight ahead, for tasks such as reading, driving, and watching television. Macular edema, or swelling, occurs when fluid leaks from retinal blood vessels and accumulates in the macula, distorting vision. Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss. About 7.7 million Americans have diabetic retinopathy. Of these, about 750,000 have DME.. DRCR.net investigators enrolled 660 people with macular edema at 88 clinical trial sites across the United States. When the study began, participants were 61 years old on average, and had had type 1 or type 2 diabetes 17 years on average. Only people with a visual acuity of 20/32 or worse were eligible to participate. (To see clearly, a person with 20/32 vision would have to be 20 ...
The Early Treatment Diabetic Retinopathy Study (ETDRS) set the guidelines for the treatment of diabetic macular edema (DME). Since that time, the standard of treatment for diabetic macular edema has been glycemic control as demonstrated by the Diabetes Control and Complications Trial (DCCT), optimal blood pressure control as demonstrated by t...
Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone Kazuki Matsuura,1 Shinichi Sasaki,2 Ryu Uotani31Nojima Hospital, Kurayoshi, 2Kushimoto Rehabilitation Center, Kushimoto, 3Tottori University, Yonago, JapanPurpose: Cystoid macular edema (CME) is associated with the use of prostaglandin eye drops after cataract surgery. The study aim was to report on the treatment of two CME patients with subtenon triamcinolone injections.Methods: Case one was a 70-year-old woman who underwent uneventful cataract surgery. Travoprost was administrated at 10 weeks after surgery, and CME occurred at 13 weeks after surgery. Case two was an 85-year-old man who underwent intraocular lens extraction and an intraocular lens suture operation. Latanoprost was readministered after the surgery. The patient complained of blurred vision 3 years later.Results: For both cases, discontinuation of the prostaglandin eye drops, subsequent initiation of treatment with diclofenac eye drops, and
BACKGROUND AND OBJECTIVE: To determine the efficacy of atorvastatin in reducing hard exudates and diabetic macular edema. PATIENTS AND METHODS: An uncontrolled clinical case series included 18 eyes with diabetic maculopathy and an elevated baseline lipid profile. All patients were treated with atorvastatin. Ophthalmologic evaluation, including fundus photography and fluorescein angiography, was performed at presentation and repeated at 3, 6, and 12 months. Hard exudates, hemorrhages, and fluorescein leakage at 12 months were evaluated and compared with baseline findings. RESULTS: Eighteen subjects with diabetic maculopathy received atorvastatin, and a significant decrease in total cholesterol and low-density lipoprotein cholesterol was seen (P | .05). Hard exudates and fluorescein leakage were decreased. No evidence of an association between change in hemorrhage status and treatment was found. CONCLUSION: Oral atorvastatin therapy in patients with diabetes mellitus and dyslipidemia seems to reduce the
Global Markets Directs, \Diabetic Macular Edema Pipeline Review, H2 2013\, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabe
Aim: To compare the anatomical and visual effects of posterior sub-tenon triamcinolone (PSTT) and intra-vitreal bevacizumab (IVB) when used as the primary treatment for diabetic macular edema (DME). Methods: In a retrospective comparative study, 58 eyes of 47 patients which have received either PSTT or IVB were analyzed. Twenty-six eyes had received PSTT 40mg/1mL of preservative free Triamcinolone-acetonide (Group I) and 32 eyes had received intravitreal injection of 1.25mg/0.05 mL of avastin (Group II). Best corrected visual acuity (BCVA) and central macular thickness prior and six weeks post procedure were studied. Complications were studied. Results: In group I, BCVA increased from 31.04±9.89 letters to 41.08±6.77 letters with an increase of 10.04±9.34 letters (P,0.001). The mean central macular thickness (CMT) in group I changed from 571.42±125.71µ to 274.73±116.76µ with a decrease of 296.7±182.34µ (P,0.001). In group II BCVA increased from 35.03±8.39 letters to 54.44±10.56 ...
Normal Eye Anatomy. Because the macula is surrounded by many tiny blood vessels, anything that affects them, such as a medical condition affecting blood vessels elsewhere in the body or an abnormal condition originating in the eye, can cause macular edema.. Retinal blood vessel obstruction, eye inflammation, and age-related macular degeneration have all been associated with macular edema. The macula may also be affected by swelling following cataract extraction, although typically this resolves itself naturally.. Treatment seeks to remedy the underlying cause of the edema. Eyedrops, injections of steroids or other, newer medicines in or around the eye, or laser surgery can be used to treat macular edema. Recovery depends on the severity of the condition causing the edema.. ...
Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell (edema). The swelling may distort a persons central vision, because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail, form, and color that is directly in the centre of the field of view. The causes of macular edema are numerous and different causes may be inter-related. It is commonly associated with diabetes. Chronic or uncontrolled diabetes type 2 can affect peripheral blood vessels including those of the retina which may leak fluid, blood and occasionally fats into the retina causing it to swell. Age-related macular degeneration may cause macular edema. As individuals age there may be a natural deterioration in the macula which can lead to the depositing of drusen under the retina sometimes with the formation of abnormal blood vessels. Replacement of the lens as ...
... Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2017, provides an overview of the Macular Edema
October 21, 2013 - Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) announced positive top-line results for Eylea (aflibercept) from the phase 3 VIBRANT trial in treating macular edema following branch retinal vein occlusion (BRVO). VIBRANT was a double-masked, randomized, active-controlled study of 183 patients with macular edema following BRVO. In the trial, 53% of patients who received aflibercept 2 mg every 4 weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study. This compares with 27% of patients in the laser group (P , .001) who had the same gain.. In addition, patients who received aflibercept 2 mg every 4 weeks achieved a 17.0-letter mean improvement over baseline in best-corrected visual acuity (BCVA) compared with a 6.9-letter mean improvement in patients who received laser (P , .0001), a key secondary endpoint.. The incidence of serious adverse events (SAE) was 9.9% in the aflibercept group and 9.8% in the laser group. One death and 1 ...
JAMA: February 2014. Importance Thickening of the center of the retina, diabetic macular edema (DME), is the most common cause of visual loss due to diabetes mellitus. Treatment of DME has improved dramatically, and the prompt diagnosis of DME and referral of these patients have become more critical. Nonetheless, awareness of and care for DME in the US population is uncharacterized.. Objective To characterize eye care and awareness of eye disease among persons with DME in the general US population.. Design, Setting, and Participants Cross-sectional analysis of data from participants in the 2005 to 2008 National Health and Nutrition Examination Survey 40 years or older with diabetes mellitus and fundus photographs.. Main Outcomes and Measures Among persons with DME, (1) awareness that diabetes has affected their eyes; (2) report on the last time they visited a diabetes specialist; (3) report on their last eye examination with pupil dilation; and (4) prevalence of visual impairment. Read ...
Diabetic macular edema (DME) is a leading cause of vision loss and blindness. Medical costs have been estimated to be about 31% higher over a 1-year period and 29% higher over a 3-year period in Medicare patients with untreated DME compared with unaffected patients with diabetes. Intravitreal antivascular endothelial growth factor inhibitors are recommended to reduce the risk of vision loss. Specialty pharmacists are integral members of a patients health care team and have a significant impact on the care and management of patients with DME. Additionally, these health care professionals may be closely involved in formulary design and agent substitution, which may decrease health care utilization and improve clinical outcomes in patients with DME ...
The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, and The Wilmer Eye Institute of Johns Hopkins University announced today that the READ 3 Study (Ranibizumab for Edema of the mAcula in Diabetes - Protocol 3 with High Dose Study) will evaluate the safety and efficacy of a injections of an antibody treatment in people with diabetic macular edema (DME).. DME is a major complication of diabetes and a leading cause of blindness in adults. In DME, leakage of fluid from the blood vessels in the eye causes the retina to swell, resulting in blurring and visual loss. The READ-3 Study is a collaboration between JDRF and Johns Hopkins University, with funding support from Genentech, Inc. (a member of the Roche group), and involves 14 clinical centers across the U.S. that will collectively enroll some 100 patients. The Wilmer Eye Institute of Johns Hopkins University will serve as the Coordinating Center for the participating clinical sites, and the ...
Aim To investigate late changes in peripheral ischemia in patients affected by diabetic macular edema (DME) and treated with repeated dexamethasone (DEX) intravitreal implants over a 1-year period.
The Retina Center of New Jersey has Extensive Experience with Retina Clinical Research in Many Clinical Areas Including Diabetic Macular Edema DME, Research Clinical Trials
The vision loss thats caused by diabetic macular edema, or DME, can trigger depression for some people. Find ways to cope with DME-related vision loss and learn ways to manage the eye disease.
The FDA recently approved Lucentis (ranibizumab) for the treatment of diabetic macular edema (DME) (swelling in the retina due to diabetes). I am intimately familiar with Lucentis as I commonly use it to treat wet age-related macular degeneration (AMD). In AMD, the use of Lucentis results in about a 94% rate of stabilizing vision (an amazing result…
Good news! Recently, Lucentis was approved for Diabetic Macular Edema. This gives Doctor Tafoya another option for the treatment of this very serious disease.
is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, RVO, diabetic macular edema and wet age-related macular degeneration. CLS-TA for suprachoroidal administration, used either alone or together with an intravitreal anti-VEGF agent, is part of Clearsides pipeline for the treatments of unmet or underserved blinding eye diseases where the pathologies manifest in the choroid and retina. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.. Cautionary Note Regarding ...
To investigate the predictive factors of clinical outcome of selective retina therapy (SRT) for diabetic macular edema (DME). This retrospective study incl
Use this page to view details for the MEDCAC Meeting for medcac meeting 3/21/2012 - anti-vegf treatment of diabetic macular edema.
From the Editor: The objective of RETINA, The Journal of Retinal and Vitreous Diseases, is to keep its readership up-to-date on the advances in their field of interest. This includes not only clinically applicable developments but also those in the clinical and translational research arenas. This newsletter highlights recent articles from the Journal that scan these objectives. The treatment of diabetic macular edema is at hand. We now have multiple modalities to approach this devastating condition. Our challenge is not only to find the best treatments available today but to continue to develop new and even better treatments in the future ...
TY - JOUR. T1 - Current insights into the management of diabetic macular edema. AU - Eichenbaum, David. AU - Albini, Thomas. AU - Fortun, Jorge A.. AU - Kitchens, John W.. AU - Reichel, Elias. PY - 2014/4. Y1 - 2014/4. UR - http://www.scopus.com/inward/record.url?scp=84899670100&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84899670100&partnerID=8YFLogxK. M3 - Comment/debate. AN - SCOPUS:84899670100. VL - APR. SP - 1. EP - 10. JO - Retina Today. JF - Retina Today. SN - 1825-0572. IS - SUPPL.. ER - ...
Diabetic macular edema is a medical condition wherein the patient loses his/her central vision to a certain degree. The condition occurs due to
Diabetic macular edema : Overview-IJCEO-Print ISSN No:-2395-1443 Online ISSN No:-2395-1451Article DOI No:-10.18231/2395-1451.2018.0036,Indian Journal of Clinical and Experimental Ophthalmology-IP Innovative Publication Pvt Limited, Medical Journals Publication, Open Access Journals, Print Journals,Indian Journals,
This study intends to evaluate the efficacy and safety of intravitreal injections of ziv-aflibercept for the treatment of patients with DME.
Diabetic macular edema: Swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula. The macula is the central portion of the retina, a small area rich in cones, the specialized nerve endings that detect color and upon which daytime vision depends. As macular edema develops, blurring occurs in the middle or just to the side of the central visual field. Visual loss from diabetic macular edema can progress over a period of months and make it impossible to focus clearly. Macular edema in common in diabetes. The lifetime risk for diabetics to develop macular edema is about 10%. The condition is closely associated with the degree of diabetic retinopathy (retinal disease). Hypertension (high blood pressure) and fluid retention also increase the hydrostatic pressure within capillaries which drives fluid from within the vessels into the retina. A common cause of fluid retention in diabetes is kidney disease with loss of protein in the urine (proteinuria). ...
Dear Editor, We read and reviewed the article entitled as "Predicting outcomes to anti- vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature by Ashraf et al. with great interest [1]. In that comprehensive study, the authors reviewed the studies that investigated demographic, clinical, optical coherence tomography (OCT), and fluorescein angiography results that could predict the outcomes of the anti-VEGF agents in patients with diabetic macular edema. Ashraf et al. suggested that choroidal thickness (CT) might also be utilized as a novel marker to predict outcomes of the treatment with anti- VEGF agents in patients with diabetic macular edema. However, we disagree with the authors at some important points. As Ashraf et al. have already indicated in their paper, CT is significantly variable in the patients with diabetic retinopathy. Although some studies stated that CT increased significantly, some others demonstrated that CT decreased ...
WEDNESDAY, Feb. 18, 2015 (HealthDay News) -- A vision-robbing condition called diabetic macular edema can strike people with diabetes.. Now, a new study compared three leading drugs for the condition -- Avastin, Eylea and Lucentis -- and found that Eylea came out on top, at least for patients with "moderate" vision loss.. The study, funded by the U.S. National Eye Institute (NEI), "will have a dramatic impact on patient care," said Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City. He was not involved in the new research.. According to the NEI, about 750,000 Americans suffer from diabetic macular edema. The condition occurs in people with a type of diabetes-related eye disease called diabetic retinopathy.. "Diabetic macular edema is the most common reason for visual loss in the 7.7 million Americans with diabetic retinopathy," Fromer noted.. "Macular edema occurs when abnormal blood vessels in the retina leak into the central area of the retina causing distorted ...
Cystoid macular edema (CME) is caused by leakage of fluid into the retina. This leakage forms cysts in the center of the retina (macula) which can be seen best with fluorescein angiography and Optical Coherence Tomography. The leakage is usually from inflammation which can result from many conditions, including cataract surgery, lens implantation, retinal detachment, inflammation in the eye ("uveitis"), diabetic retinopathy and macular degeneration. The treatment depends on the cause. CME is most commonly found after cataract surgery. In these cases eye drops are first tried, including topical non-steroidal anti-inflammatory medications (NSAIDS) and steroids. If the edema does not resolve, a steroid injection behind the eye may be tried. Finally, vitrectomy surgery may be required to remove the vitreous gel which may be pulling on the macula causing inflammation and leakage. It is important to realize that CME can result even following perfect cataract surgery. In fact, as many as 25 percent or ...
... treatment is offered by eye specialists in NMC Eyecare. Macular edema is a condition accumulation fluid inside eye.
PURPOSE: Little is known about the costs of cystoid macular edema (CME), an important complication associated with cataract surgery. The purpose of this analysis was to estimate the cost of treatment for CME in the United States. METHODS: Data were analyzed from the 1997 through 2001 Medicare 5% Beneficiary Encrypted Files. Beneficiaries who underwent cataract surgery were